Pinpin Zhu, Dan Wu, Yan Wang, Xiaoxue Liu, Lance E Rodewald, Yixing Li, Hui Zheng, Lei Cao, Yifan Song, Li Song, Xiaodong Zhao, Jianyi Yao, Fuzhen Wang, Mingshuang Li, Qian Zhang, Tingting Yan, Zundong Yin
{"title":"Effectiveness of DTaP Against Pertussis in ≤2-Year-Old Children - Linyi Prefecture, Shandong Province, China, 2017-2019.","authors":"Pinpin Zhu, Dan Wu, Yan Wang, Xiaoxue Liu, Lance E Rodewald, Yixing Li, Hui Zheng, Lei Cao, Yifan Song, Li Song, Xiaodong Zhao, Jianyi Yao, Fuzhen Wang, Mingshuang Li, Qian Zhang, Tingting Yan, Zundong Yin","doi":"10.46234/ccdcw2023.071","DOIUrl":null,"url":null,"abstract":"<p><strong>What is already known about this topic?: </strong>Vaccine effectiveness (VE) is positively correlated with the number of administered co-purified diphtheria, tetanus, and acellular pertussis vaccine (DTaP) doses. A matched case-control study conducted in Zhongshan City revealed that the co-purified DTaP VE against pertussis-related illnesses in children aged 4-11 months was 42% for one dose, 88% for two doses, and 95% for three doses, respectively.</p><p><strong>What is added by this report?: </strong>The results of this study contribute to the current body of research. We found that the VE of co-purified DTaP against pertussis-related illness and hospitalization increased substantially, ranging from 24%-26% after one dose to 86%-87% after four doses.</p><p><strong>What are the implications for public health practice?: </strong>The results of this study underscore the significance of prompt and comprehensive immunization using co-purified DTaP to decrease the incidence of pertussis. Additionally, these findings offer evidence supporting the modification of China's pertussis vaccination approach.</p>","PeriodicalId":9867,"journal":{"name":"China CDC Weekly","volume":"5 17","pages":"374-378"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f3/df/ccdcw-5-17-374.PMC10184384.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"China CDC Weekly","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46234/ccdcw2023.071","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
What is already known about this topic?: Vaccine effectiveness (VE) is positively correlated with the number of administered co-purified diphtheria, tetanus, and acellular pertussis vaccine (DTaP) doses. A matched case-control study conducted in Zhongshan City revealed that the co-purified DTaP VE against pertussis-related illnesses in children aged 4-11 months was 42% for one dose, 88% for two doses, and 95% for three doses, respectively.
What is added by this report?: The results of this study contribute to the current body of research. We found that the VE of co-purified DTaP against pertussis-related illness and hospitalization increased substantially, ranging from 24%-26% after one dose to 86%-87% after four doses.
What are the implications for public health practice?: The results of this study underscore the significance of prompt and comprehensive immunization using co-purified DTaP to decrease the incidence of pertussis. Additionally, these findings offer evidence supporting the modification of China's pertussis vaccination approach.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
